BioCentury | Sep 28, 2018
Emerging Company Profile

GDF11 against aging

Harvard University spinout Elevian Inc. is developing a regenerative platform around GDF11 to treat age-related diseases, including Alzheimer's disease. The company, which emerged from stealth on Sept. 6, aims to modulate the protein’s pathway with...
BioCentury | Sep 18, 2018
Company News

Management tracks: BioTime, Immune-Onc

...$33 million in a series B round from Northern Light Venture Capital, Vivo Capital and Stanford-StartX Fund...
BioCentury | Sep 7, 2018
Financial News

Anti-aging Elevian debuts with $5.5M seed funding

Regenerative medicine company Elevian Inc. (Allston, Mass.) launched on Sept. 6 with $5.5 million in seed funding from Bold Capital, WTI, Stanford StartX fund, Longevity Fund, Kizoo Ventures, Thynk Capital and additional undisclosed investors. Elevian...
BioCentury | Mar 23, 2018
Financial News

AI company twoXAR raises $10M series A

...raised $4.3 million in seed funding from investors including Andreessen Horowitz, CLI Ventures and the Stanford-StartX Fund...
BioCentury | Mar 19, 2018
Financial News

AI company twoXAR raises $10M series A

...raised $4.3 million in seed funding from investors including Andreessen Horowitz, CLI Ventures and the Stanford-StartX Fund...
BioCentury | Jun 6, 2016
Financial News

AccuraGen completes venture financing

AccuraGen Holdings Ltd. , Menlo Park, Calif. Business: Diagnostic Date completed: 2016-06-01 Type: Venture financing Raised: $40 million Investors: Junson Capital; Decheng Capital; Temasek; DT Capital; Stanford StartX Fund; Nan Fung Capital; existing investors WIR Staff...
BioCentury | Jun 2, 2016
Financial News

AccuraGen raises $40M in series B

...$40 million in a series B round. Junson Capital, Decheng Capital, Temasek Investments, DT Capital, Stanford-StartX Fund...
BioCentury | Feb 18, 2016
Emerging Company Profile

A need for speed

Bioinformatics play twoXAR Inc. aims to condense years of wet-lab compound discovery and lead prioritization into minutes. The company has created an in silico platform that uses machine learning to build a mathematical disease model...
BioCentury | Nov 23, 2015
Financial News

twoXAR completes venture financing

twoXAR Inc. , Palo Alto, Calif. Business: Bioinformatics Date completed: 2015-11-18 Type: Venture financing Raised: $3.4 million Investors: Andreessen Horowitz; CLI Ventures; Stanford StartX Fund WIR Staff...
BioCentury | Nov 17, 2014
Emerging Company Profile

Swift western wind

Zephyrus Biosciences Inc. is developing its scWestern technology to perform Western blots on thousands of cells with single-cell resolution, which will enable researchers to study how protein concentrations vary within heterogeneous cell populations quickly and...
Items per page:
1 - 10 of 14
BioCentury | Sep 28, 2018
Emerging Company Profile

GDF11 against aging

Harvard University spinout Elevian Inc. is developing a regenerative platform around GDF11 to treat age-related diseases, including Alzheimer's disease. The company, which emerged from stealth on Sept. 6, aims to modulate the protein’s pathway with...
BioCentury | Sep 18, 2018
Company News

Management tracks: BioTime, Immune-Onc

...$33 million in a series B round from Northern Light Venture Capital, Vivo Capital and Stanford-StartX Fund...
BioCentury | Sep 7, 2018
Financial News

Anti-aging Elevian debuts with $5.5M seed funding

Regenerative medicine company Elevian Inc. (Allston, Mass.) launched on Sept. 6 with $5.5 million in seed funding from Bold Capital, WTI, Stanford StartX fund, Longevity Fund, Kizoo Ventures, Thynk Capital and additional undisclosed investors. Elevian...
BioCentury | Mar 23, 2018
Financial News

AI company twoXAR raises $10M series A

...raised $4.3 million in seed funding from investors including Andreessen Horowitz, CLI Ventures and the Stanford-StartX Fund...
BioCentury | Mar 19, 2018
Financial News

AI company twoXAR raises $10M series A

...raised $4.3 million in seed funding from investors including Andreessen Horowitz, CLI Ventures and the Stanford-StartX Fund...
BioCentury | Jun 6, 2016
Financial News

AccuraGen completes venture financing

AccuraGen Holdings Ltd. , Menlo Park, Calif. Business: Diagnostic Date completed: 2016-06-01 Type: Venture financing Raised: $40 million Investors: Junson Capital; Decheng Capital; Temasek; DT Capital; Stanford StartX Fund; Nan Fung Capital; existing investors WIR Staff...
BioCentury | Jun 2, 2016
Financial News

AccuraGen raises $40M in series B

...$40 million in a series B round. Junson Capital, Decheng Capital, Temasek Investments, DT Capital, Stanford-StartX Fund...
BioCentury | Feb 18, 2016
Emerging Company Profile

A need for speed

Bioinformatics play twoXAR Inc. aims to condense years of wet-lab compound discovery and lead prioritization into minutes. The company has created an in silico platform that uses machine learning to build a mathematical disease model...
BioCentury | Nov 23, 2015
Financial News

twoXAR completes venture financing

twoXAR Inc. , Palo Alto, Calif. Business: Bioinformatics Date completed: 2015-11-18 Type: Venture financing Raised: $3.4 million Investors: Andreessen Horowitz; CLI Ventures; Stanford StartX Fund WIR Staff...
BioCentury | Nov 17, 2014
Emerging Company Profile

Swift western wind

Zephyrus Biosciences Inc. is developing its scWestern technology to perform Western blots on thousands of cells with single-cell resolution, which will enable researchers to study how protein concentrations vary within heterogeneous cell populations quickly and...
Items per page:
1 - 10 of 14